Consistent with hepatic histology results, reduced plasma hepatic function biomarkers aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were observed in MCFA-treated groups than in the CML-treated group. This evidence concerns the gene GPT and chronic myelogenous leukemia, BCR-ABL1 positive.